Novartis Field Medical Reorg 2012













FWIW - I've seen increase activity among my Novartis LinkedIn contacts.

Here they go again...

1) Lost Tekturna and its product family - huge loss in cardiovascular space

2) Gilenya - is it doing as well is it should be?

3) Vaccines - only need so many people covering these products

4) Oncology - ??

At least KM is no longer around.